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Abstract
As a consequence of multiple functions of p53, its activation in response to cytotoxic stress may have pro-
apoptotic or protective effects depending on the nature of lesions. We have previously shown that mutational
inactivation of p53 results in sensitization to paclitaxel. In this study, we used cyclic pifithrin-α, a transcriptional
inhibitor of p53, to further investigate the relevance of p53 function in the response of tumor cells to microtubule
inhibitors. Using drug concentrations causing only antiproliferative effects, the combination of antimicrotubule
agents with subtoxic pifithrin-α doses resulted in increase of sensitivity of two wild type p53 cell lines, associated
with a substantial M phase cell accumulation and marked sensitization to apoptosis. Pifithrin-α had no sensitizing
effect in p53 defective cells or a marginal effect in normal human fibroblasts. The apoptotic response to the com-
bination was concomitant with p21 down-regulation, Polo-like kinase 1 up-regulation, p34cdc2 kinase dephosphory-
lation, and cdc25C phosphatase phosphorylation, supporting mitotic arrest. Sensitization to paclitaxel-induced
apoptosis was also achieved by p53-siRNA transfection in wild type p53 H460 cells. Pifithrin-α did not enhance
the apoptotic response after p53 down-regulation. The results support a protective role of the transcriptional
activity of p53 in response to mitotic spindle damage. The inhibition of transcriptional activity of p53 may have
therapeutic implications in the treatment of p53 wild type tumors with antimitotic agents.
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Introduction
p53 function is a transcription factor, and it induces the expression of
genes involved in cell cycle control, DNA repair, and apoptosis [1–
4]. The p53 tumor suppressor plays a central role in the response to
diverse stress stimuli [1–5]. Cell fate after activation of p53 depends
on the biologic context and on the nature of response to the cyto-
toxic stress. P21WAF1, a p53 target protein, has been implicated as a
major determinant of cell fate under stress conditions (e.g., DNA
damage), because it participates in both G1 and G2 checkpoints.
p53 can be activated also in response to mitotic spindle damage
[6–11]. Checkpoint mechanisms play a critical role in controlling cell
cycle progression and DNA repair under stress conditions, such as
exposure to cytotoxic agents. Therefore, cell cycle checkpoint func-
tion is considered to be an important determinant of cellular sen-
sitivity to various antitumor agents.
The mutation of p53 is a frequent event in most tumors (∼50%)
resulting in the inactivation of its transactivating function. p53 mu-
tations may affect the apoptotic response to some p53-activating
agents such as DNA-damaging agents (e.g., platinum compounds
and alkylating agents) [12,13]. However, the influence of p53 status
is likely dependent on the nature of cytotoxic stress, because wild
type p53 also has a protective function through the activation of
p53-dependent checkpoints [14]. Indeed, we have found that ovarian
carcinoma cells selected for resistance to cisplatin and characterized
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by mutational inactivation of p53 are hypersensitive to paclitaxel
[15]. In ovarian carcinoma cells with mutant p53, paclitaxel treat-
ment caused apoptosis after progressing to a G1-like status and
DNA endoreduplication [16].
The present study is an additional attempt to analyze the impact of
p53 function on cellular response to antimicrotubule agents with the
use of cyclic pifithrin-α (PFT), a chemical inhibitor of p53 [17,18].
The results indicate that treatment with the PFT analog in combina-
tion with various antimicrotubule agents enforced cell accumulation
in mitosis, resulting in a dramatic increase of apoptosis without evi-
dence of progression to a G1-like status. The available results support
that the transcriptional activity of p53 has a protective role in re-
sponse to mitotic spindle damage.
Materials and Methods
Cell Culture and Drugs
The human ovarian carcinoma cell line IGROV-1 and the cisplatin-
resistant subline IGROV-1/Pt1, selected by exposure to increasing
drug concentration [12], the human lung adenocarcinoma cell line
H460, the human prostate cell line PC3, and the human osteo-
sarcoma cell line SAOS were grown in RPMI 1640 (Lonza, Vierviers,
Belgium) containing 10% fetal bovine serum (Life Technologies,
Inc., Gaithersburg, MD) in 5% CO2 at 37°C. Human normal em-
bryonic lung fibroblasts were kindly provided by E. Prosperi (Univer-
sity of Pavia, Italy) and grown in Eagle’s minimum essential medium
(Lonza) supplemented with 10% fetal bovine serum (Life Tech-
nologies). Paclitaxel (Indena, Milan, Italy), thiocolchicine, and PFT
(Calbiochem EMD Chemicals, Inc., La Jolla, CA) were dissolved in
dimethyl sulfoxide (DMSO); vinorelbine (Navelbine, Pierre Fabre,
Castres, France) was dissolved in H2O before use. In all experiments,
cells were exposed to PFT 2 hours before treatment with antimicro-
tubule agents. The highest final concentration of DMSO in culture
medium was 0.5%.
Antiproliferative Activity
Cells were seeded in duplicate into six-well plates. After 24 hours,
cells were exposed to the cyclic form of PFT and to antimicrotubule
agents or to both simultaneously for 72 hours. After treatment, ad-
herent cells were trypsinized and counted by a cell counter (Coulter
Electronics, Luton, UK) [19]. Analysis of drug interaction was done
by a modified method of Drewinko et al. [20]: Drewinko index
>1 indicates greater than additive effects (synergism; the higher the
value, the greater the degree of synergy), Drewinko index =1 indi-
cates additivity, and Drewinko index <1 indicates antagonism. In
all experiments, control cells were treated with the solvent at the
same concentration used in drug-exposed cells. When indicated,
the method described by Chou and Talalay [21] was also applied.
Cell Cycle, Apoptosis, and CPP32 Activity
For cell cycle analysis, cells were trypsinized, fixed in 70% etha-
nol, stained in phosphate-buffered saline (PBS) containing 10 μg/
ml propidium iodide (PI; Sigma, St. Louis, MO) and RNase A
(66 U/ml; Sigma) for 18 hours, analyzed by FACScan flow cytometer
(Becton Dickinson, Mountain View, CA). For apoptosis detection,
adherent and floating cells were harvested and analyzed for DNA
fragmentation by terminal deoxynucleotidyl transferase–mediated
nick end labeling (TUNEL) assay (Roche, Mannheim, Germany) ac-
cording to the manufacturer’s recommendation. Apoptosis was as-
sessed by flow cytometer, and the results were analyzed using the
CellQuest software (Becton Dickinson). For the analysis of CPP32
activity (Oncogene Sciences, Uniondale, NY), adherent and floating
cells were harvested and processed as described by the manufacturer.
After washing, cells were resuspended in wash buffer, the CPP32 ac-
tivity was detected by flow cytometer (FACScan), and the results
were analyzed using the CellQuest software.
Western Blot Analysis
Adherent and floating cells were lysed in hot sodium dodecyl sul-
fate (SDS) sample buffer, and whole-cell lysates were prepared for
SDS–polyacrylamide gel electrophoresis (PAGE): 0.125 M Tris–
HCl (pH 6.8), 5% SDS, 1 mM phenylmethylsulfonyl fluoride,
10 μg/ml pepstatin, 12.5 μg/ml leupeptin, 100 Komberg inter-
national units of aprotinin, 1 mM sodium orthovanadate. Samples
were separated by SDS-PAGE and were transferred onto nitro-
cellulose filters. Blots were preblocked for 2 hours at room tem-
perature in PBS containing 5% (w/v) dried nonfat milk. Filters
were incubated overnight at 4°C with antibody anti–mitotic protein
monoclonal 2 (MPM-2) and –Polo-like kinase 1 (Plk1; Upstate Bio-
technology, Lake Placid, NY); anti–Raf-1 (E-10, sc-7267), –cyclin
B1 (GNS1, sc-245), –cdc-25C (C-20, sc-327), –SNK/Plk2 (H-90,
sc-25421), and –cyclin A (BF683, SC-239) (all from Santa Cruz Bio-
technology, Santa Cruz, CA); anti–Bcl-2 and -p53 (Dako, Glostrup,
Denmark); anti-p21 (Neomarker, Union City, CA); anti–PARP-1
(Oncogene Sciences); anti–cytochrome C and -Rb (BD Pharmingen,
Becton Dickinson); anti–cleaved caspase 3 and anti–phospho-AKT
(Ser473; Cell Signaling Technology, Beverly, MA); anti-cdc2 (Tyr15-
phospho–specific; New England BioLabs, Beverly, MA); anti-actin
and –β-tubulin (Sigma); anti-HSP70 mitochondrial (Abcam, Ltd.,
Cambridge, UK); and anti–PKBα/AKT (Transduction Laboratories,
Lexington, NY).
Tubulin Polymerization Assay
Cells were seeded at a density of 1 × 106 cells in 10-cm Petri
dishes. The day after, cells were exposed to paclitaxel/PFT combined
treatment and, 24 hours later, were processed for the tubulin poly-
merization assay. Samples were prepared as described by Blagosklonny
et al. [22] and Cassinelli et al. [16] and separated by SDS-PAGE
(10% resolving gel and 3% stacking gel), and tubulin distribution
was analyzed by immunoblot analysis using a mouse anti–β-tubulin
antibody (Sigma).
Analysis of Cytochrome C Release and
Subcellular Fractionation
H460 and IGROV-1 cells were exposed to paclitaxel (IC50 or
IC80) alone or combined with the cyclic form of PFT. Cells were
washed in PBS added with 0.1 mM ice-cold sodium orthovanadate
and then incubated in permeabilization buffer (20 mM HEPES–
KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 250 mM sucrose, 0.5 mM phenylmethylsulfonyl fluoride,
10 μg/ml leupeptin, 10 μg/ml aprotinin, and 10 μg/ml trypsin in-
hibitor) for 15 minutes in ice. Cells were homogenized using a glass
Dounce and pestle for approximately 50 strokes. After two centrifuga-
tion cycles at 3000 rpm for 10 minutes, the supernatants were again
centrifuged at 14,000 rpm for 30 minutes. Cytosolic fraction was
analyzed by immunoblot analysis.
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Immunofluorescence Analysis
H460 and IGROV-1 cell lines were treated with either PFT or
paclitaxel alone or with their combination for 24 hours. After washing
with PBS, the cells were fixed in 2% paraformaldehyde for 30 min-
utes and permeabilized with ice-cold methanol for 20 minutes at
−20°C. After blocking with PBA (PBS containing 1% bovine serum
albumin), anti-p53 antibody (DO7; Dako) was incubated for 1 hour
at room temperature followed by incubation with Alexa Fluor
488 goat antimouse IgG secondary antibody (Molecular Probes,
Eugene, OR) for 1 hour. Images were observed and analyzed by con-
focal microscopy (Microradiance 2000; Bio-Rad Laboratories, Inc.,
Hercules, CA) equipped with Kr/Ar (488 nm), HeNe (543 nm),
and diode (638 nm) lasers. Images (525 × 525 pixels) were obtained
using a ×60 oil immersion lens and were analyzed using Image-Pro
Plus software (Version 6.0; Media Cybernetics, Inc., Bethesda, MD).
Reported images represent a single Z-section of the samples (23–
51 stacks), with 0.48-μm step. The pinhole diameter was regulated
according to the value suggested by the acquisition software to obtain
the maximum resolution power.
Small Interfering RNA Transfection
Small interfering RNAs were synthesized by Invitrogen Corp.
(Carlsbad, CA). The p53-siRNA consisted of a mixture of two
siRNA duplexes targeting for a different region of the p53 mRNA
(Validated stealth RNAi DuoPak). A pool of two nontarget-
ing siRNA duplexes was used as a negative control medium GC
duplex (Invitrogen).
Transfection of cells with siRNA duplexes was performed using
Lipofectamine 2000 Reagent (Invitrogen). H460 were transfected
with control siRNA or p53-siRNA at a final concentration of
100 nM for 24 hours. After silencing, cells were replated and treated
on the second day with PFT for 2 hours and, after that, with pacli-
taxel, as indicated. Gene silencing effects were evaluated by Western
blot also on the day of the treatment.
Results
Cell Growth Inhibition
The effects of the combination of the p53 inhibitor of cyclic PFT
and antimicrotubule agents were investigated in two human cancer
cell lines with wild type p53 (IGROV-1 and H460), in a cisplatin-
resistant subline (IGROV-1/Pt) characterized by a mutant p53 and
in two p53 defective cell lines (PC3 prostate carcinoma and SAOS
osteosarcoma). Cells were pretreated for 2 hours with subtoxic PFT
concentrations (in the range of IC10–IC30) followed by a simulta-
neous 72-hour exposure to the antimitotic agent (paclitaxel, vino-
relbine, or thiocolchicine; Figure 1). The IGROV-1 cells were less
sensitive to the antimitotic agents than the H460 cell (IC50 values
for paclitaxel 0.12 ± 0.02 and 0.03 ± 0.004 μM, respectively). In
contrast, IGROV-1 cells, characterized by a higher level of p53 ex-
pression, were more sensitive to the antiproliferative effects of PFT.
The pattern of sensitivity of these cell lines was apparently consistent
with the level of p53 protein. Dose–response curves of various anti-
microtubule agents in combination with subtoxic concentrations of
PFTrevealed a supraadditive effect in both IGROV-1 and H460 cells
(Figure 1, A and B). The combination of PFTwas synergic with both
microtubule-stabilizing and -destabilizing drugs. The synergistic in-
teraction was more marked in the H460 cell line. The analysis of
drug interaction according to the method of Drewinko et al. [20]
and to that of Chou and Talalay [21] confirmed that the antimitotic
agents/PFT combination was synergic. Figure 1C shows the analy-
sis of interaction for paclitaxel and PFT, according to the method
of Chou and Talalay [21]. On the contrary, PFT did not affect the
dose–response curve of paclitaxel in a cisplatin-resistant subline
(IGROV-1/Pt) carrying the mutant p53, in prostate PC3 cells, and
in osteosarcoma SAOS cells characterized by the loss of p53 expres-
sion (Figure 1D), suggesting that the sensitization observed in
IGROV-1 or in H460 cells was related to the inhibition of the func-
tional p53 by PFT. To better support this interpretation, we studied
the effect of paclitaxel in H460 cells after transfection with p53-
siRNA (Figure 1E ). p53 silencing substantially reduced the ac-
cumulation of the p53 protein caused by paclitaxel treatment and
resulted in a sensitization to paclitaxel comparable to the effect of
PFT/paclitaxel combination in control cells. Under the same treat-
ment conditions, PFT produced only a marginal sensitization to
paclitaxel of “normal” human fibroblasts (Figure 1F ).
Cell Cycle Analysis
Because induction of mitotic arrest is a hallmark of microtubule
inhibitors, we examined the cell cycle perturbation of H460 and
IGROV-1 cells exposed to paclitaxel, vinorelbine, thiocolchicine
(IC50), or to their combination with PFT. Whereas PFT itself did
not induce modifications of the cell cycle distribution of H460 cells,
at the concentrations used, the antimicrotubule agents caused only
inhibition of cell proliferation with a moderate increase of cells
in G2/M. In spite of this behavior, H460 cells exhibited a normal
mitotic spindle checkpoint, because higher concentrations (IC80)
caused mitotic arrest (not shown). A similar behavior has been
described in other cell lines [23,24]. Pretreatment with PFT and
24 hours of simultaneous treatment with a low concentration of
the antimicrotubule drug caused a cell accumulation in G2/M in
H460 cells (Figure 2A). In IGROV-1 cells, paclitaxel alone caused
an evident increase in the number of cells in the G2/M phase
(Figure 2A). The accumulation of cells in the G2/M phase was en-
hanced with the PFT combined treatment in a dose-dependent man-
ner. In particular, treatment with paclitaxel alone resulted in 50% cell
accumulation in G2/M, and the combination with PFT (10 μM) en-
hanced the number of G2/M phase cells to 80%. The combination
induced a marked increase of sub-G1 fraction in both cell lines. At
drug concentrations that produced a low (<20%) extent of mitosis
in wild type p53 cells, the addition of PFT resulted in a marked in-
crease of mitotic cells as determined by the analysis with PI staining
(Figure 2B). Again, the effect of combined treatment on the cell cycle
was more evident in H460 cells that were also more responsive to the
drug combination.
Tubulin Polymerization
To investigate the drug effects on the microtubule system, we
compared cells treated with paclitaxel (IC50) or with PFT combi-
nation for 24 hours (Figure 2C ). In H460 and IGROV-1 cells, the
paclitaxel/PFT combination enhanced the tubulin polymerization
induced by paclitaxel. This effect is consistent with the increase of
mitotic cells.
Modulation of Biochemical Markers of Mitotic Arrest
To gain further insight into the mechanism of cell arrest in the
M phase, we performed additional investigation with PFT/paclitaxel
combination. In cells exposed for 24 hours to the paclitaxel/PFT
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Figure 1. Antiproliferative effects of paclitaxel (PTX), vinorelbine (VIN), or thiocolchicine (TIO) in H460 (A); IGROV-1 (B); IGROV/Pt1, PC3,
SAOS (D) and human normal fibroblasts (F) in the absence (▪) or presence of 20 μM (•), 10 μM (▾), and 2 μM (○) cyclic PFT. Cells werepretreated with the indicated concentrations of PFT for 2 hours before the combined treatment for 72 hours. Pifithrin-α was used at two
subtoxic concentrations (i.e., 2 μM PFT was equivalent to IC15 in IGROV-1 cells; 10 μM PFT was equivalent to IC10 in H460 and SAOS
and to IC20 in IGROV-1, IGROV-1/Pt, human fibroblasts and PC3; 20 μM PFT was equivalent to IC20 in H460 and SAOS and to IC30 in
IGROV-1/Pt and PC3). (E) Effects of paclitaxel (▪) and its combination with PFT 10 μM (▾) in H460-negative control cells and effects
of paclitaxel in p53-siRNA–transfected cells (□). The p53 expression analysis is also shown. The negative control cells are referred to
cells transfected with RNAi-negative control duplex containing 48% GC. Cell transfection was performed as indicated in the Materials
and Methods section. (Inset C) combination index calculated according to the Chou and Talalay analysis [21] for paclitaxel/PFT interaction.
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combination, the mitotic arrest was confirmed by the increase of
mitosis-specific phosphorylated epitopes recognized by MPM-2 anti-
body (Figure 2D). This enhancement was less evident in IGROV-1
cells, because paclitaxel alone produced an up-regulation of phospho-
proteins in keeping with the accumulation of cells in the M phase.
A hyperphosphorylation of Raf-1 and Bcl-2 is a biochemical hall-
mark of the cellular response to microtubule inhibitors, because these
events are associated with the M phase [22,25]. In H460 cells, the
PFT/paclitaxel combination treatment for 24 hours induced a parallel
mobility shift of Bcl-2 and Raf-1 in SDS-PAGE, thereby supporting a
Figure 2. Cell cycle perturbation and analysis of mitotic arrest and of mitotic biochemical markers in cells pretreated for 2 hours with PFT
followed by simultaneous 24-hour exposure to antimicrotubule agents (IC50). (A) Cell cycle distribution of H460 and IGROV-1. The rep-
resentative of at least three independent experiments is shown. (B) Mitotic index in PI-stained H460 and in IGROV-1 cells determined by
fluorescence microscope analysis. The results are expressed as a percentage of the total cell population and are the mean ± SD of three
independent experiments. (C) Analysis of the tubulin polymerization in H460 and in IGROV-1 cells. Cell fractionation was performed as
indicated in the Materials and Methods section. Soluble cytosolic (S) or polymerized (P) tubulin was detected in cell fractions by Western
blot analysis after 24 hours of exposure. (D) Activation of mitosis-related factors in H460 and IGROV-1 cells. Western blot analysis of cell
lysates was performed at the end of treatment (24 hours). β-Tubulin is shown as a control for protein loading.
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drug-induced phosphorylation of the two proteins (Figure 2D). In ad-
dition, the combined treatment induced dephosphorylation of p34cdc2
kinase (at Tyr15), phosphorylation of cdc25C phosphatase, and
up-regulation of cyclin B1. In IGROV-1 cells, no change in the phos-
phorylation of Raf-1 and Bcl-2 was detected between the treatment
with paclitaxel alone or with the combination. However, after the
combination treatment, cells showed a reduction of the phosphoryla-
tion of p34cdc2 kinase and an increase of phosphorylation of cdc25C.
Pifithrin-α itself caused a down-regulation of the phosphorylation of
p34cdc2, most evident at 10 μM. Moreover, paclitaxel combined with
the higher dose of PFT induced an increase of the cyclin B1 protein
levels. This event supported that PFT induced in paclitaxel-treated
cells a mitotic arrest without progression to the G1-like phase.
The activation of Plk1 (a member of the Polo-like kinase family)
is implicated in various processes that contribute to the activation of
cyclin B/p34cdc2 complex [26]. After 24 hours of exposure, in H460
cells paclitaxel alone did not modify the Plk1 expression, whereas the
PFT/paclitaxel combination caused a substantial up-regulation of
Plk1. In IGROV-1 cells, paclitaxel alone caused a moderate increase
of Plk1 protein, in keeping with the appearance of G2/M peak,
MPM-2 reactivity, and phosphorylation of Raf-1 and Bcl-2. The PFT
combination produced only a moderate increase of Plk1 expression.
Plk2, another member of the Polo-like kinase family activated
during the DNA damage checkpoint in G2 phases, has been reported
to be a p53 target, and the p53-dependent activation of Snk/Plk2
prevents mitotic catastrophe after spindle damage [8]. However, no
modulation of Plk2 could be detected in H460 and in IGROV-1
cells in our experimental conditions (data not shown).
Apoptotis Induction and Caspase Activation
We tested the hypothesis that the sensitization effect of PFT was
related to an enhanced cell susceptibility to antimicrotubule agent–
induced apoptosis. The CPP32 activity assay and the TUNEL assay
for the analysis of apoptotic response were performed in cells exposed
to low concentrations of the antimicrotubule agents (paclitaxel,
vinorelbine, or thiocolchicine), which caused only antiproliferative
effects, or to their combination with subtoxic PFT concentrations
for 72 hours. In both H460 and IGROV-1 cells, the FACScan analy-
sis of CPP32-positive cells supported the increase in the activation
of CPP32 after 72 hours of combined treatments (Figure 3A). In-
deed, PFT induced a remarkable increase of apoptosis in paclitaxel-,
vinorelbine-, or thiocolchicine-treated cells (Figure 3B). A sensitiza-
tion to paclitaxel-induced apoptosis was not observed in “normal”
human fibroblasts (Figure 3B), thus supporting a low susceptibility
to apoptosis of normal cells.
Because proapoptotic stimuli induced by mitotic spindle damage
involved mitochondrial pathway, we performed Western blot analy-
sis of the release of cytochrome C in H460 and IGROV-1 cells at
24 hours after treatment (Figure 3C ). Compared with the effect of
paclitaxel alone, an increased release of cytochrome C at 24 hours
was found in the combined treatment in a PFT dose-dependent
manner. According to the release of cytochrome C after 24 hours
of combined treatment, the apoptosis activation was further sup-
ported by Western blot analysis of caspase cleavage (Figure 3D).
Barely detectable caspase activation was induced by the two drugs
given alone. In contrast, in cells treated with a drug combination,
a marked cleavage of caspase 3 was associated with the cleavage of
the caspase substrate PARP-1, thus confirming an enhancement of
the caspase-dependent apoptotic pathways. The synergistic activa-
tion of caspase, already observed at 24 hours after treatment, was
more marked after 48 hours. The release of cytochrome C and
caspase 3 activation were concomitant with the appearance of mitotic
cells. Because under the same conditions approximately 80% of the
treated cells are arrested in mitosis (Figure 2, A and B), this finding
supports the interpretation that cells treated with the combination
underwent apoptosis during mitosis.
In contrast to control H460 cells, the p53-siRNA–transfected cells
was able to undergo apoptosis after 24 hours of exposure to a low
dose of paclitaxel (0.03 μM), thus supporting the proposed protec-
tive role of p53 (Figure 3E ). As expected, as a consequence of sup-
pression of the p53 expression, this effect was not enhanced by the
addition of PFT under these conditions.
Expression of p53 and p21WAF1/Cip1
The expression level of p53 and p21WAF1/Cip1 was investigated by
Western blot analysis 24 hours after drug treatment. As shown in
Figure 4A, paclitaxel determined a marked increase of p53 and
p21 expressions in both IGROV-1 and H460 cells. Pifithrin-α had
no effect on paclitaxel-induced p53 activation but had reduced the
up-regulation of p21 induced by paclitaxel, likely because of the
inhibition of p53 transcriptional activity. At the used subtoxic con-
centrations, PFT itself was unable to modify the basal expression of
p21. As expected, a marginal or no induction of p21 was detected in
H460 cells after p53 down-regulation with p53-siRNA (Figure 4B).
Analysis by confocal microscopy revealed an increased amount of
p53 in the nuclei of cells exposed to a low paclitaxel concentration
(IC50; not shown). In contrast, the combination of PFT with pacli-
taxel resulted in a widespread distribution of p53 in the cytoplasm.
Modulation of AKT
Because AKT is involved in the cellular response to taxanes [16,27],
we examined the state of activation of this kinase in H460 and
IGROV-1 cells treated with paclitaxel alone or with PFT combination
for 24 hours (Figure 5). In both cell lines, AKT phosphorylation at
Ser473 was marginally modulated by paclitaxel or PFT alone. On the
contrary, the combination of paclitaxel with PFT resulted in a sub-
stantial decrease of AKT phosphorylation in H460 or IGROV-1 cells,
associated with a down-regulation of AKT protein itself.
Discussion
In this study, we have found that the inhibition of p53 transcrip-
tional function by a specific chemical inhibitor, cyclic PFT, resulted
in a marked sensitization to antimitotic agent–induced apoptosis of
human tumor cells, carrying functional wild type p53. The sensiti-
zation in the combined treatment was produced by all the tested
antimicrotubule agents, including both microtubule-stabilizing drugs
(taxanes) and compounds that inhibit tubulin assembly (e.g., vinca
alkaloids), and occurred at concentrations that caused only anti-
proliferative effects. Thus, subtoxic concentrations of the p53 inhib-
itor converted the growth-inhibitory effect of the antimicrotubule
agent in a cytotoxic outcome as evidenced by a dramatic enhance-
ment of the apoptotic response. Sensitization to paclitaxel was also
found in wild type p53 cells after suppression of the p53 expression
by siRNA. No or only a marginal sensitization by PFTwas detected
in cells characterized by defective p53 or after down-regulation of
p53 by siRNA, supporting that sensitization to drug-induced apop-
tosis by PFTwas closely related to the modulation of p53 functions,
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Figure 3. Induction of apoptosis and analysis of apoptosis-related factors in H460 and in IGROV-1 cells exposed to the IC50 paclitaxel
(PTX), vinorelbine (VIN), thiocolchicine (TIO), cyclic PFT, or their combination. Cells were pretreated with PFT for 2 hours and then ex-
posed to the antimicrotubule agent. (A) Caspase 3 (CPP32) activity after 72 hours of treatment determined with the colorimetric assay
kit (Calbiochem) according to the manufacturer’s protocol and analyzed by FACScan. The results, expressed as percentage of CPP32
activity-positive cells, are the mean ± SD of two independent experiments. (B) Apoptosis determined by TUNEL assay and FACScan
analysis after 72 hours of treatment. The percentages of TUNEL-positive cells are indicated in each panel. Representative of at least
three independent experiments is shown. (C) Release of cytochrome C into the cytosol. The cytosolic extracts were prepared after
24 hours of treatment with paclitaxel alone or combined with PFT. An antibody against the mitochondrial marker HSP70-mitochondrial
was used as protein control to ensure the subcellular fractionation process. As a control for HSP70-mitochondrial antibody, a mitochon-
drial extract containing HSP70 (ctr+) is shown. (D) Cleavage of CPP32 and PARP-1. Western blot analysis with specific antibodies was
performed after 24 hours of treatment. β-Tubulin is shown as a control of protein loading. The arrows indicate the cleavage products.
(E) Caspase 3 activation and PARP fragmentation in response to paclitaxel (24 hours of exposure) after p53 down-regulation in p53-
siRNA–transfected H460 cells.
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which could play a protective role. Our results are consistent with the
observation that activation of p53 by MDM2 antagonists provides
protection from cytotoxicity of paclitaxel [28].
The two wild type p53 cell lines were characterized by a somewhat
different response to antimicrotubule agents in terms of perturbation
of cell cycle progression. Indeed, the treatment with low concentra-
tions of antimitotic agents causing only antiproliferative effects re-
sulted in a G2/M phase accumulation that was moderate in H460
cells but substantial in IGROV-1 cells. Under these conditions, no
appreciable induction of apoptosis could be detected in both cell
lines, as indicated by the lack of release of cytochrome C and of
the caspase activation. In contrast, the combination of the micro-
tubule inhibitor with PFT enhanced the accumulation of cells in
the M phase, with a marked increase of apoptosis in both cell lines.
Low paclitaxel concentrations may cause inhibition of cell pro-
liferation without mitotic arrest, because under these conditions,
the drug may induce both p53 and p21 causing G1 and G2 arrests
[23,24]. A similar behavior was observed in H460 cells, exhibiting
a partial delay in G1 and a low accumulation in late G2, and in
IGROV-1 cells, exhibiting a more evident G2/M arrest. Pifithrin-α
abolished in both cell lines the paclitaxel-induced up-regulation of
p21 after the activation of p53. This event reflected the inhibition
of the transcriptional activity of p53, because p21 is a gene target
of p53. The implication of p21 in response to paclitaxel is consistent
with a parallel sensitization produced by p53 down-regulation in
p53-siRNA–transfected cells. Down-regulation of p21 is expected
to allow the activation of the cyclin B/p34cdc2 complex [29–31],
which is inactive in the G2 phase. Activation of the complex, indi-
cated by the reduced phosphorylation of p34cdc2 at Tyr15, should
allow a G2→M transition. However, a number of factors are known
to be involved in regulating mitotic entry. In particular, the activation
of Plk1 is expected to promote the activation of cyclin B/p34cdc2
complex, because it is implicated in the phosphorylation and activa-
tion of cdc25C, a phosphatase involved in the dephosphorylation of
p34cdc2 at Tyr15 [26,32]. Moreover, Plk1 regulates the degradation
of Wee1 (implicated in the G2 checkpoint) after phosphorylation
[26]. Indeed, under our conditions, down-regulation of p21 in cells
treated with PFT/paclitaxel combination was associated with the
activation of p34cdc2/cyclin B complex, an increase of cdc25C phos-
phorylation, and up-regulation of Plk1, thus supporting a suppres-
sion of G2 checkpoint and a facilitation of G2/M transition [26].
A protective role of p21 against cytotoxicity of paclitaxel has been
described [31,33,34], but the cellular and molecular bases of this
protection are not clearly defined. Besides its involvement in multiple
cell cycle checkpoints, p21 could confer resistance to antimicrotubule
agents by a decrease of mitotic arrest and exit from abnormal mitosis
[33,35,36]. In addition, p21 is implicated in the AKT-dependent
survival pathway, because cytoplasmic accumulation of p21 in
paclitaxel-treated cells could be regulated by an AKT-dependent
Figure 4. Expression of p53 and p21waf1 in H460, IGROV-1 cells (A) and H460 cells transfected with RNAi-negative control duplex or with
p53-siRNA (B) treated for 24 hours with paclitaxel (IC50, PTX) or cyclic PFT alone or their combination. In the combined treatment, PFT
were added 2 hours before treatment with PTX. (A) Whole-cell extracts were prepared and analyzed by Western blot analysis. β-Tubulin
is shown as a control of protein loading. For p21WAF1, low and high film exposures are shown.
Figure 5. Down-regulation of AKT and inhibition of AKT phosphory-
lation (Ser473) detected by Western blot analysis in H460 and
IGROV-1 cells exposed to paclitaxel (IC50) and cyclic PFT in single
or combined treatment. Cells were pretreated for 2 hours with
PFT followed by simultaneous 24-hour exposure to the antimicro-
tubule agent. Filters were stripped and reprobed with the anti-
body recognizing AKT protein or β-tubulin to control specific or
overall protein loading.
594 Sensitization to Apoptosis by p53 Inhibition Zuco and Zunino Neoplasia Vol. 10, No. 6, 2008
phosphorylation [37]. In our study, the down-regulation of p21 in-
duced by PFT in paclitaxel-treated cells (Figure 4) was associated
with the release of cytochrome C and the activation of caspase 3 after
24 hours of combined treatment (Figure 3, C and D). Because
p21 has been implicated in the inhibition of the caspase activation
process [38], the observed down-regulation may also have a pro-
apoptotic effect.
The observed sensitization of mitotic cells by PFT could reflect
at least in part a prevalence of apoptotic signals likely activated in
a p53-independent manner. In particular, although a direct involve-
ment of p53 in the modulation of the AKT-dependent survival path-
way remains to be documented in our cell systems, the available
results showed an inhibition of both up-regulation and phosphoryla-
tion of AKT induced by paclitaxel. Because a protective role of AKT
against taxane-induced apoptosis has been described in other cell
systems [27], it is conceivable that inactivation of AKT-mediated sur-
vival pathway may favor a cell death process.
In conclusion, the present observations of the sensitization to anti-
microtubule agents by a transcriptional inhibitor of p53 are consistent
with multiple and sometimes opposite functions of p53, depending on
the nature of cytotoxic stress. The available evidence supports that, in
response to mitotic spindle damage, the transcription-mediated func-
tions of p53 have a protective action. However, after inhibition of the
transcriptional activity, p53 could retain proapoptotic functions that
might be prevalent over antiapoptotic signals. The sensitization of
tumor cells with wild type p53 by selective inhibition of p53 function
described in this study may have obvious implications in the antitumor
therapy with antimitotic agents. Indeed, it supports the potential effi-
cacy of regimens containing low (and less toxic) doses of antimitotic
agents by combination with a nontoxic modulating agent. The use of
rational combinations could improve the efficacy of protracted treat-
ment regimens with low doses of taxanes that are known to have anti-
angiogenic and antitumor effects [39]. The use of p53 inhibitors has
been proposed as a chemoprotective strategy to reduce the side effects
caused by chemotherapy or radiotherapy or by other stress conditions
implicating the activation of p53 [17]. The present study supports the
potential use of PFT as a chemosensitizing agent in combination with
microtubule inhibitors. In contrast to the protective effect of PFT
against toxicity of DNA-damaging agents, the combination with anti-
microtubule drugs could enhance toxicity against normal tissue. The
potential therapeutic advantages of the combination of p53 inhibitors
with antimicrotubule agents remain to be documented in in vivo
models, for improvement of the “therapeutic index.” However, it
should be emphasized that tumor cells seem to be more susceptible
to apoptotic death than nonmalignant cells, as supported by a lack
of sensitization to paclitaxel-induced apoptosis in human “normal”
fibroblasts (Figure 3B).
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